FLUOGUIDE A/S DK -1 (96X) - Net Assets
Based on the latest financial reports, FLUOGUIDE A/S DK -1 (96X) has net assets worth €54.53 Million EUR (≈ $63.75 Million USD) as of December 2025. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (€88.29 Million ≈ $103.22 Million USD) and total liabilities (€33.76 Million ≈ $39.47 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check 96X cash and liquid asset ratio to evaluate the company's liquid asset resilience ratio.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | €54.53 Million |
| % of Total Assets | 61.76% |
| Annual Growth Rate | 8.95% |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | 77.84 |
FLUOGUIDE A/S DK -1 - Net Assets Trend (2021–2025)
This chart illustrates how FLUOGUIDE A/S DK -1's net assets have evolved over time, based on quarterly financial data. Also explore FLUOGUIDE A/S DK -1 (96X) total assets for the complete picture of this company's asset base.
Annual Net Assets for FLUOGUIDE A/S DK -1 (2021–2025)
The table below shows the annual net assets of FLUOGUIDE A/S DK -1 from 2021 to 2025. For live valuation and market cap data, see 96X company net worth.
| Year | Net Assets | Change |
|---|---|---|
| 2025-12-31 | €54.53 Million ≈ $63.75 Million |
+136.39% |
| 2024-12-31 | €23.07 Million ≈ $26.97 Million |
+81.34% |
| 2023-12-31 | €12.72 Million ≈ $14.87 Million |
-60.21% |
| 2022-12-31 | €31.97 Million ≈ $37.37 Million |
-17.40% |
| 2021-12-31 | €38.70 Million ≈ $45.25 Million |
-- |
Equity Component Analysis
This analysis shows how different components contribute to FLUOGUIDE A/S DK -1's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 40.8% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (December 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | €52.89 Million | 97.00% |
| Other Components | €1.64 Million | 3.00% |
| Total Equity | €54.53 Million | 100.00% |
FLUOGUIDE A/S DK -1 Competitors by Market Cap
The table below lists competitors of FLUOGUIDE A/S DK -1 ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
International Conveyors Limited
NSE:INTLCONV
|
$57.07 Million |
|
Aerodrome Group Ltd
TA:ARDM
|
$57.07 Million |
|
Eastside Distilling, Inc.
NASDAQ:BLNE
|
$57.08 Million |
|
Edip Gayrimenkul Yatirim Sanayi ve Ticaret AS
IS:EDIP
|
$57.10 Million |
|
BIT Computer Co. Ltd
KQ:032850
|
$57.06 Million |
|
IMPACT Silver Corp.
V:IPT
|
$57.03 Million |
|
Petra Diamonds Ltd
LSE:PDL
|
$57.02 Million |
|
Mount Logan Capital Inc
NEO:MLC
|
$57.00 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in FLUOGUIDE A/S DK -1's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 23,067,000 to 54,528,000, a change of 31,461,000 (136.4%).
- Net loss of 39,459,000 reduced equity.
- New share issuances of 70,366,000 increased equity.
- Other factors increased equity by 554,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | €-39.46 Million | -72.36% |
| Share Issuances | €70.37 Million | +129.05% |
| Other Changes | €554.00K | +1.02% |
| Total Change | €- | 136.39% |
Book Value vs Market Value Analysis
This analysis compares FLUOGUIDE A/S DK -1's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 1.11x
- The company is trading above its book value, indicating the market recognizes value beyond its reported assets.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2021-12-31 | €3.42 | €3.69 | x |
| 2022-12-31 | €2.71 | €3.69 | x |
| 2023-12-31 | €1.04 | €3.69 | x |
| 2024-12-31 | €1.69 | €3.69 | x |
| 2025-12-31 | €3.34 | €3.69 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently FLUOGUIDE A/S DK -1 utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -72.36%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 1.62x
- Recent ROE (-72.36%) is above the historical average (-129.31%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2021 | -61.42% | 0.00% | 0.00x | 1.38x | €-27.64 Million |
| 2022 | -85.52% | 0.00% | 0.00x | 1.11x | €-30.54 Million |
| 2023 | -301.71% | 0.00% | 0.00x | 2.33x | €-39.65 Million |
| 2024 | -125.54% | 0.00% | 0.00x | 1.23x | €-31.27 Million |
| 2025 | -72.36% | 0.00% | 0.00x | 1.62x | €-44.91 Million |
Industry Comparison
This section compares FLUOGUIDE A/S DK -1's net assets metrics with peer companies in the Biotechnology industry.
Industry Context
- Industry: Biotechnology
- Average net assets among peers: $979,793,893
- Average return on equity (ROE) among peers: -18.73%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| FLUOGUIDE A/S DK -1 (96X) | €54.53 Million | -61.42% | 0.62x | $57.06 Million |
| TIZIANA LIFE SCIENCES LTD (0RP) | $5.54 Million | -319.56% | 1.20x | $157.03 Million |
| Theravance Biopharma Inc (0TB) | $441.80 Million | 197.40% | 0.37x | $828.57 Million |
| PreveCeutical Medical Inc (18H) | $-3.60 Million | 0.00% | 0.00x | $3.34 Million |
| Argen-X (1AE) | $2.53 Billion | -16.11% | 0.12x | $44.01 Billion |
| WAVE LIFE SCIENCES LTD. (1U5) | $-45.09 Million | 0.00% | 0.00x | $1.12 Billion |
| ZAI LAB LTD0000006 (1ZLB) | $840.90 Million | -30.57% | 0.41x | $2.05 Billion |
| BioNTech SE (22UA) | $1.37 Billion | 1.11% | 0.69x | $23.24 Billion |
| Ascletis Pharma Inc (2VJ) | $2.98 Billion | -7.02% | 0.03x | $2.05 Billion |
| ALPHAMAB ONCOLO.DL-000002 (3NK) | $1.67 Billion | -12.59% | 0.28x | $978.26 Million |
| BIOMIND LABS INC. (3XI) | $-1.43 Million | 0.00% | 0.00x | $3.31 Million |
About FLUOGUIDE A/S DK -1
FluoGuide A/S, a clinical stage biotechnology company, develops drugs for precision cancer surgery in Denmark. The company offers FG001, an urokinase-type plasminogen activator receptor target imaging agent, which is in Phase II clinical trial for the treatment of high-grade glioma and lung, head, and neck cancer; and functions as a photosensitizer, which is in pre-clinical stage for the treatmen… Read more